• SINTX Technologies posted a net loss of USD 2.82 million for the three months ended March 31, 2026, widening 23% from the year-ago period.
• Revenue rose 3% to USD 380,000, while gross profit increased 17% to USD 144,000.
• Operating loss widened 35% to USD 3.21 million as operating expenses climbed 34% to USD 3.35 million, led by a 92% jump in general and administrative costs to USD 2.54 million.
• Sales and marketing expense more than doubled to USD 399,000, while research and development expense fell 67% to USD 364,000 on lower headcount-related costs and a reallocation of overhead to general and administrative expense.
• Management said revenue recognized in Q1 from the FDA 510(k)-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System is expected to increase throughout 2026, while substantial doubt remains about the company’s ability to continue as a going concern for at least 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SINTX Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023919), on May 15, 2026, and is solely responsible for the information contained therein.